[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562887":3},{"organization":4,"outcomesModule":7,"designInfo":49,"detailedDescription":55,"studyPopulation":48,"armGroups":56,"interventions":90,"overallOfficials":48,"centralContacts":95,"locations":101,"responsibleParty":463,"collaborators":48,"id":465,"slug":48,"hasResults":466,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":48,"eligibilityCriteria":470,"healthyVolunteers":466,"sex":471,"minAge":472,"maxAge":48,"enrollmentInfo":473,"targetDuration":48,"studyType":476,"phases":477,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":104,"whyStopped":48,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":495},{"fullName":5,"class":6},"Shenzhen Ionova Life Sciences Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":23,"otherOutcomes":48},[9,13,17,20],{"measure":10,"description":11,"timeFrame":12},"Phase 1: Maximum tolerated dose (MTD)","The highest dose level at which at least 6 patients have been treated and less than 33% of patients experienced a DLT.","Within first 28 days of treatment",{"measure":14,"description":15,"timeFrame":16},"Phase 1: Recommended dose range (RDR)","The RDR will be determined based on the PK and PD data, the preliminary clinical activity of INV-9956, as well as the incidence rate and nature of the toxicities observed in subsequent cycles beyond Cycle 1","12 months",{"measure":18,"description":19,"timeFrame":16},"Phase 2: Evaluate Radiographic progression-free survival (rPFS)","To evaluate rPFS per PCWG-modified RECIST v1.1 (soft tissue response) and PCWG3 criteria (bone metastases)",{"measure":21,"description":22,"timeFrame":16},"Phase 2: Evaluate overall response rate (ORR)","To evaluate ORR per PCWG-modified RECIST v1.1 (soft tissue response) and PCWG3 criteria (bone metastases)",[24,27,30,33,36,38,40,42,44,46],{"measure":25,"description":26,"timeFrame":16},"Phase 1: Characterize the safety of INV-9956 as assessed by CTCAE v5.0","To analyze the safety profile of INV-9956 as a single agent by AE, clinical lab test results, ECG and Vital signs changes",{"measure":28,"description":29,"timeFrame":16},"Phase 1: Determine the PK using AUC of INV-9956","To determine the pharmacokinetics (PK) using AUC of INV-9956 after a single dose and at steady state after multiple doses",{"measure":31,"description":32,"timeFrame":16},"Phase 1: Determine the PK using Cmax of INV-9956","To determine the pharmacokinetics (PK) using Cmax of INV-9956 after a single dose and at steady state after multiple doses",{"measure":34,"description":35,"timeFrame":16},"Phase 1: Determine the blood concentration of steroid hormone","To determine the blood concentration of steroid hormones at various timepoints as PD markers for INV-9956",{"measure":37,"description":19,"timeFrame":16},"Phase 1: Evaluate Radiographic progression-free survival (rPFS)",{"measure":39,"description":22,"timeFrame":16},"Phase 1: Evaluate overall response rate (ORR)",{"measure":41,"description":26,"timeFrame":16},"Phase 2: Characterize the safety of INV-9956 as assessed by CTCAE v5.0",{"measure":43,"description":29,"timeFrame":16},"Phase 2: Determine the PK using AUC of INV-9956",{"measure":45,"description":32,"timeFrame":16},"Phase 2: Determine the PK using Cmax of INV-9956",{"measure":47,"description":35,"timeFrame":16},"Phase 2: Determine the blood concentration of steroid hormone",null,{"allocation":50,"interventionModel":51,"interventionModelDescription":48,"primaryPurpose":52,"observationalModel":48,"timePerspective":48,"maskingInfo":53},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":54,"maskingDescription":48,"whoMasked":48},"NONE","This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.\n\nThe entire study consists of two parts: Phase 1 for dose escalation and Phase 2 for dose expansion.\n\nPhase 1 dose escalation of INV-9956 follows a real time monitored, PK\u002FPD and safety guided scheme with a traditional 3+3 design for DLT assessment.\n\nPhase 2 aims to reassure the safety profile and better define efficacy. Phase 2 consists of up to 2 cohorts by different AR gene status:\n\n* Cohort A: AR mutant CRPC\n* Cohort B: AR wide-type CRPC (optional) Currently enrolling patients under Phase 2.",[57,63,67,71,75,78,82,86],{"label":58,"type":59,"description":60,"interventionNames":61},"Phase 1 INV-9956 Dose escalation Dose level 1","EXPERIMENTAL","INV-9956 Dose escalation Dose level 1 is co-administered with dexamethasone and fludrocortisone acetate",[62],"Drug: INV-9956",{"label":64,"type":59,"description":65,"interventionNames":66},"Phase 1 INV-9956 Dose escalation Dose level 2","INV-9956 Dose escalation Dose level 2 is co-administered with dexamethasone and fludrocortisone acetate",[62],{"label":68,"type":59,"description":69,"interventionNames":70},"Phase 1 INV-9956 Dose escalation Dose level 3","INV-9956 Dose escalation Dose level 3 is co-administered with dexamethasone and fludrocortisone acetate",[62],{"label":72,"type":59,"description":73,"interventionNames":74},"Phase 2 INV-9956 Dose expansion - Cohort A","INV-9956 is co-administered with dexamethasone and fludrocortisone acetate",[62],{"label":76,"type":59,"description":73,"interventionNames":77},"Phase 2 INV-9956 Dose expansion - Cohort B",[62],{"label":79,"type":59,"description":80,"interventionNames":81},"Phase 1 INV-9956 Dose escalation beyond the optimal dose - Dose level 4","INV-9956 Dose escalation Dose level 4 is co-administered with dexamethasone and fludrocortisone acetate",[62],{"label":83,"type":59,"description":84,"interventionNames":85},"Phase 1 INV-9956 Dose escalation beyond the optimal dose - Dose level 5","INV-9956 Dose escalation Dose level 5 is co-administered with dexamethasone and fludrocortisone acetate",[62],{"label":87,"type":59,"description":88,"interventionNames":89},"Phase 1 INV-9956 Dose escalation beyond the optimal dose - Dose level 6","INV-9956 Dose escalation Dose level 6 is co-administered with dexamethasone and fludrocortisone acetate",[62],[91],{"type":92,"name":93,"description":73,"armGroupLabels":94,"otherNames":48},"DRUG","INV-9956",[58,64,68,79,83,87,72,76],[96],{"name":97,"role":98,"phone":99,"phoneExt":48,"email":100},"Yi Zhu, MD, MBA","CONTACT","1 908 240 7514","yi.zhu@ionovabio.com",[102,124,141,157,174,190,207,224,243,259,274,295,311,327,340,356,372,390,406,421,437,449],{"facility":103,"status":104,"city":105,"state":106,"zip":107,"country":108,"countryCode":109,"cosmosGeoPoint":110,"geoPoint":115,"contacts":116},"Honor Health","RECRUITING","Scottsdale","Arizona","85258","United States","US",{"type":111,"coordinates":112},"Point",[113,114],-111.89903,33.50921,{"lat":114,"lon":113},[117,121],{"name":118,"role":98,"phone":48,"phoneExt":119,"email":120},"Andrea House","480-323-1791","clinicaltrials@honorhealth.com",{"name":122,"role":123,"phone":48,"phoneExt":48,"email":48},"Michael Gordon, MD","PRINCIPAL_INVESTIGATOR",{"facility":125,"status":104,"city":126,"state":127,"zip":128,"country":108,"countryCode":109,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Hoag Family Cancer Institute","Newport Beach","California","92663",{"type":111,"coordinates":130},[131,132],-117.92895,33.61891,{"lat":132,"lon":131},[135,139],{"name":136,"role":98,"phone":137,"phoneExt":48,"email":138},"Patrice Jones","9497645501","clinicaltrials.@hoag.org",{"name":140,"role":123,"phone":48,"phoneExt":48,"email":48},"David Benjamin, MD",{"facility":142,"status":104,"city":143,"state":127,"zip":144,"country":108,"countryCode":109,"cosmosGeoPoint":145,"geoPoint":149,"contacts":150},"UC Irvine Medical Center","Orange","92868",{"type":111,"coordinates":146},[147,148],-117.85311,33.78779,{"lat":148,"lon":147},[151,155],{"name":152,"role":98,"phone":153,"phoneExt":48,"email":154},"Hazel Dimasuay","714-509-2170","hdimasua@hs.uci.edu",{"name":156,"role":123,"phone":48,"phoneExt":48,"email":48},"Edward Uchio, MD",{"facility":158,"status":104,"city":159,"state":160,"zip":161,"country":108,"countryCode":109,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Next Oncology - Houston","Houston","Texas","77054",{"type":111,"coordinates":163},[164,165],-95.36327,29.76328,{"lat":165,"lon":164},[168,172],{"name":169,"role":98,"phone":170,"phoneExt":48,"email":171},"Paige Day","(210) 580-9480","pday@nextoncology.com",{"name":173,"role":123,"phone":48,"phoneExt":48,"email":48},"Peter DeMaria, MD",{"facility":175,"status":104,"city":176,"state":160,"zip":177,"country":108,"countryCode":109,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"UT Health","San Antonio","78229",{"type":111,"coordinates":179},[180,181],-98.49363,29.42412,{"lat":181,"lon":180},[184,188],{"name":185,"role":98,"phone":186,"phoneExt":48,"email":187},"Epp Goodwin","210-450-5798","goodwine@uthscsa.edu",{"name":189,"role":123,"phone":48,"phoneExt":48,"email":48},"John Sarantopoulos, MD",{"facility":191,"status":104,"city":192,"state":193,"zip":194,"country":108,"countryCode":109,"cosmosGeoPoint":195,"geoPoint":199,"contacts":200},"NEXT Oncology","Fairfax","Virginia","22031",{"type":111,"coordinates":196},[197,198],-77.30637,38.84622,{"lat":198,"lon":197},[201,205],{"name":202,"role":98,"phone":203,"phoneExt":48,"email":204},"Blake Patterson","703-783-4505","bpatterson@nextoncology.com",{"name":206,"role":123,"phone":48,"phoneExt":48,"email":48},"Mohamed Salkeni, MD",{"facility":208,"status":104,"city":209,"state":210,"zip":211,"country":108,"countryCode":109,"cosmosGeoPoint":212,"geoPoint":216,"contacts":217},"Summit Cancer Centers","Spokane","Washington","99208",{"type":111,"coordinates":213},[214,215],-117.42908,47.65966,{"lat":215,"lon":214},[218,222],{"name":219,"role":98,"phone":220,"phoneExt":48,"email":221},"Monika Chaudhry","509-251-8973","Monika.Chaudhry@aoncology.com",{"name":223,"role":123,"phone":48,"phoneExt":48,"email":48},"Arvind Chaudhry, MD, PhD",{"facility":225,"status":226,"city":227,"state":228,"zip":48,"country":229,"countryCode":230,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"Beijing GoBroad Hospital","NOT_YET_RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":111,"coordinates":232},[233,234],116.39723,39.9075,{"lat":234,"lon":233},[237,241],{"name":238,"role":98,"phone":239,"phoneExt":48,"email":240},"Chuanliang Cui, MD, PhD","13691489319","1008ccl@163.com",{"name":242,"role":123,"phone":48,"phoneExt":48,"email":48},"Chuanliang Cui, MD",{"facility":244,"status":104,"city":245,"state":246,"zip":247,"country":229,"countryCode":230,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"The First Affiliated Hospital of Fujian Medical University","Fuzhou","Fujian","350005",{"type":111,"coordinates":249},[250,251],119.30611,26.06139,{"lat":251,"lon":250},[254,258],{"name":255,"role":98,"phone":256,"phoneExt":48,"email":257},"Ning Xu","+86-13235907575","drxun@163.com",{"name":255,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":260,"status":226,"city":261,"state":262,"zip":48,"country":229,"countryCode":230,"cosmosGeoPoint":263,"geoPoint":267,"contacts":268},"The First People's Hospital of Foshan","Foshan","Guangdong",{"type":111,"coordinates":264},[265,266],113.13148,23.02677,{"lat":266,"lon":265},[269,273],{"name":270,"role":98,"phone":271,"phoneExt":48,"email":272},"Rong Huang","+86-18038865000","nnjbhg@163.com",{"name":270,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":275,"status":104,"city":276,"state":277,"zip":278,"country":229,"countryCode":230,"cosmosGeoPoint":279,"geoPoint":283,"contacts":284},"He'nan Cancer Hospital","Zhengzhou","He'Nan","450000",{"type":111,"coordinates":280},[281,282],113.64861,34.75778,{"lat":282,"lon":281},[285,289,293,294],{"name":286,"role":98,"phone":287,"phoneExt":48,"email":288},"Tiejun Yang","+86-13967189416","hxj319@163.com",{"name":290,"role":98,"phone":291,"phoneExt":48,"email":292},"Xingjiang Hu","+86-136537129999","tirjunyang@163.com",{"name":286,"role":123,"phone":48,"phoneExt":48,"email":48},{"name":290,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":296,"status":226,"city":297,"state":298,"zip":299,"country":229,"countryCode":230,"cosmosGeoPoint":300,"geoPoint":304,"contacts":305},"Hu'nan Cancer Hospital","Changsha","Hu'Nan","410006",{"type":111,"coordinates":301},[302,303],112.97087,28.19874,{"lat":303,"lon":302},[306,310],{"name":307,"role":98,"phone":308,"phoneExt":48,"email":309},"Shusuan Jiang","+86-18608408523","jiangshusuan@hnca.org.cn",{"name":307,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":312,"status":104,"city":313,"state":314,"zip":315,"country":229,"countryCode":230,"cosmosGeoPoint":316,"geoPoint":320,"contacts":321},"Nanjing Drum Tower Hospital","Nanjing","Jiangsu","210008",{"type":111,"coordinates":317},[318,319],118.77778,32.06167,{"lat":319,"lon":318},[322,326],{"name":323,"role":98,"phone":324,"phoneExt":48,"email":325},"Hongqian Guo","+86-13605171690","gymwpi@126.com",{"name":323,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":328,"status":226,"city":329,"state":330,"zip":48,"country":229,"countryCode":230,"cosmosGeoPoint":331,"geoPoint":335,"contacts":336},"The First Affiliated Hospital of Nanchang University","Nanchang","Jiangxi",{"type":111,"coordinates":332},[333,334],115.85306,28.68396,{"lat":334,"lon":333},[337],{"name":338,"role":98,"phone":339,"phoneExt":48,"email":48},"Cheng Zhang","+86-13607080357",{"facility":341,"status":104,"city":342,"state":343,"zip":344,"country":229,"countryCode":230,"cosmosGeoPoint":345,"geoPoint":349,"contacts":350},"Liaoning Cancer Hospital","Shenyang","Liaoning","110801",{"type":111,"coordinates":346},[347,348],123.43278,41.79222,{"lat":348,"lon":347},[351,355],{"name":352,"role":98,"phone":353,"phoneExt":48,"email":354},"Yu Zeng","+86-18040097265","zeng_yu03@163.com",{"name":352,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":357,"status":104,"city":358,"state":359,"zip":360,"country":229,"countryCode":230,"cosmosGeoPoint":48,"geoPoint":48,"contacts":361},"Shandong Cancer Hospital","Ji'nan","Shandong","250000",[362,366,370,371],{"name":363,"role":98,"phone":364,"phoneExt":48,"email":365},"Yuping Sun","+86-13370582181","13370582181@163.com",{"name":367,"role":98,"phone":368,"phoneExt":48,"email":369},"Jiasheng Bian","+86-15954104097","sdbjs232466@sina.com",{"name":363,"role":123,"phone":48,"phoneExt":48,"email":48},{"name":367,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":373,"status":104,"city":374,"state":375,"zip":376,"country":229,"countryCode":230,"cosmosGeoPoint":377,"geoPoint":381,"contacts":382},"Fudan University Shanghai Cancer Center","Shanghai","Shanghai Municipality","200032",{"type":111,"coordinates":378},[379,380],121.45806,31.22222,{"lat":380,"lon":379},[383,387,389],{"name":384,"role":98,"phone":385,"phoneExt":48,"email":386},"Jian Zhang","+86-21-64175590","syner2000@163.com",{"name":388,"role":123,"phone":48,"phoneExt":48,"email":48},"Dingwei Ye",{"name":384,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":391,"status":104,"city":392,"state":393,"zip":394,"country":229,"countryCode":230,"cosmosGeoPoint":395,"geoPoint":399,"contacts":400},"Tianjin Medical University Cancer Institute & Hospital","Tianjin","Tianjin Municipality","300202",{"type":111,"coordinates":396},[397,398],117.17667,39.14222,{"lat":398,"lon":397},[401,405],{"name":402,"role":98,"phone":403,"phoneExt":48,"email":404},"Xin Yao","+86-13803000688","yaoxin@tjmuch.com",{"name":402,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":407,"status":226,"city":408,"state":409,"zip":48,"country":229,"countryCode":230,"cosmosGeoPoint":410,"geoPoint":414,"contacts":415},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","Hubei","Wuhan",{"type":111,"coordinates":411},[412,413],120.41732,29.08114,{"lat":413,"lon":412},[416,420],{"name":417,"role":98,"phone":418,"phoneExt":48,"email":419},"Xiaoping Zhang, MD, PhD","+86-18602752025","xzhang@hust.edu.cn",{"name":417,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":422,"status":104,"city":423,"state":424,"zip":425,"country":229,"countryCode":230,"cosmosGeoPoint":426,"geoPoint":430,"contacts":431},"The First Affiliated Hospital, School of Medicine, Zhejiang University","Hangzhou","Zhejiang","310003",{"type":111,"coordinates":427},[428,429],120.16142,30.29365,{"lat":429,"lon":428},[432,436],{"name":433,"role":98,"phone":434,"phoneExt":48,"email":435},"Peng Zhao","+86-13958124783","zhaop@zju.edu.cn",{"name":433,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":438,"status":226,"city":423,"state":424,"zip":439,"country":229,"countryCode":230,"cosmosGeoPoint":440,"geoPoint":442,"contacts":443},"Zhejiang Provincial People's Hospital","310014",{"type":111,"coordinates":441},[428,429],{"lat":429,"lon":428},[444,448],{"name":445,"role":98,"phone":446,"phoneExt":48,"email":447},"Dahong Zhang","+86-13858019285","zjsgcp@126.com",{"name":445,"role":123,"phone":48,"phoneExt":48,"email":48},{"facility":450,"status":226,"city":451,"state":424,"zip":48,"country":229,"countryCode":230,"cosmosGeoPoint":452,"geoPoint":456,"contacts":457},"The First Affiliated Hospital of Wenzhou Medical University","Wenzhou",{"type":111,"coordinates":453},[454,455],120.66682,27.99942,{"lat":455,"lon":454},[458,462],{"name":459,"role":98,"phone":460,"phoneExt":48,"email":461},"Wei Chen","+86 577 5557 9937","2818777033@qq.com",{"name":459,"role":123,"phone":48,"phoneExt":48,"email":48},{"type":464,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR","100562887",false,"NCT06609005","A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","A Phase 1 and Phase 2, Multi-Center, Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Evidence of Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer","Inclusion Criteria:\n\n1. Written informed consent obtained.\n2. Male aged ≥ 18 years.\n3. Histologically confirmed adenocarcinoma of the prostate.\n4. Castration resistant prostate cancer with serum testosterone \\\u003C50 ng\u002FdL.\n5. Metastatic disease.\n6. Ongoing androgen deprivation therapy with GnRH analogue or antagonist, or have had bilateral orchiectomy.\n7. Received at least one prior line of taxane-based chemotherapy and at least one line of hormonal AR targeted therapy (eg, abiraterone, enzalutamide). Patients who have refused or were intolerant to taxane-based chemotherapy may be enrolled.\n8. ECOG performance status 0-1.\n9. Adequate marrow, liver and kidney function.\n10. INR ≤1.5.\n11. Able to swallow study treatment.\n12. Has a life expectancy of \\> 3 months.\n\nExclusion Criteria:\n\n1. Have a medical condition such as Crohn's disease or have undergone significant surgery to the gastrointestinal tract that could impair absorption or that could result in short bowel syndrome with diarrhea due to malabsorption.\n2. History of pituitary or adrenal dysfunction.\n3. Poorly controlled diabetes mellitus.\n4. Clinically significant abnormality in serum potassium and sodium.\n5. Have a serious nonmalignant disease (eg, hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the Investigator and\u002For the Sponsor.\n6. Active or unstable cardio-\u002Fcerebro-vascular disease, including thromboembolic events.\n7. History of congestive heart failure; cardiac disease, myocardial infarction within 6 months prior to enrollment.\n8. Prolonged QTcF interval.\n9. Active infection or other medical condition that would make corticosteroid contraindicated.","MALE","18 Years",{"count":474,"type":475},84,"ESTIMATED","INTERVENTIONAL",[478,479],"PHASE1","PHASE2","This is a Phase 1 and Phase 2 study to evaluate the safety and antitumor activity of INV-9956 in adult patients with advanced metastatic Castration Resistant Prostate Cancer.",[482],"Advanced Metastatic Castration Resistant Prostate Cancer",[484,485],"mCRPC","Prostate Cancer","2026-06-02",{"date":488,"type":489},"2026-06-04","ACTUAL",{"date":491,"type":489},"2025-01-23",{"date":493,"type":475},"2028-01-17",{"name":5,"class":6},22]